Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 302Terminated 79Unknown 22Withdrawn 16Active not recruiting 12Recruiting 8No longer available 2Suspended 1Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 47Breast Neoplasms 46Colorectal Neoplasms 28Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Glioblastoma 19Pancreatic Neoplasms 17Melanoma 17Lung Neoplasms 17Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Rectal Neoplasms 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Sarcoma 6Leukemia 6

Interventions

zanubrutinib 1Vincristine 1Rituximab 1Prednisone 1Epirubicin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Congenital Abnormalities × Clear all
NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Suspended
59 enrolled
Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡